Hubbry Logo
Polybrominated diphenyl ethersPolybrominated diphenyl ethersMain
Open search
Polybrominated diphenyl ethers
Community hub
Polybrominated diphenyl ethers
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Polybrominated diphenyl ethers
Polybrominated diphenyl ethers
from Wikipedia

Polybrominated diphenyl ethers
Chemical structure of PBDEs
Identifiers
ECHA InfoCard 100.082.305 Edit this at Wikidata
Properties
C12H10−xBrxO
Molar mass Variable
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Polybrominated diphenyl ethers or PBDEs, are a class of organobromine compounds that are used as flame retardants. Like other brominated flame retardants, PBDEs have been used in a wide array of products, including building materials, electronics, furnishings, motor vehicles, airplanes, plastics, polyurethane foams,[1] and textiles. They are structurally akin to polychlorinated diphenyl ethers (PCDEs), polychlorinated biphenyls (PCBs) and other polyhalogenated compounds, consisting of two halogenated aromatic rings. PBDEs are classified according to the average number of bromine atoms in the molecule. The life-saving benefits of fire retardants led to their popularization. Standards for mass transit vehicles continues to increase as of 2021.[2]: 1–26 

Because of their toxicity and persistence, all commercially relevant PBDEs have been marked for elimination under the Stockholm Convention, a treaty to control and phase out major persistent organic pollutants (POPs).[3][4]

Classes of PBDEs

[edit]

The family of PBDEs consists of 209 possible substances, which are called congeners (PBDE = C12H(10−x)BrxO (x = 1, 2, ..., 10 = m + n)). The number of isomers for mono-, di-, tri-, tetra-, penta-, hexa-, hepta-, octa-, nona-, and decabromodiphenyl ethers are 3, 12, 24, 42, 46, 42, 24, 12, 3 and 1, respectively.[5]

Lower-brominated PBDEs with 1–4 bromine atoms per molecule are regarded as more dangerous because they more efficiently bioaccumulate. They have been known to affect thyroid hormone levels, and studies have linked them to reproductive and neurological risks at certain concentrations or higher.[6] Higher-brominated PBDEs are less acutely dangerous but biotically and photochemically debrominate to lower-brominated congeners.[7]

number formula name CAS Number InChIKey
PBDE-1 C12H9BrO 2-bromodiphenyl ether 36563-47-0 RRWFUWRLNIZICP-UHFFFAOYSA-N
PBDE-2 C12H9BrO 3-bromodiphenyl ether 6876-00-2 AHDAKFFMKLQPTD-UHFFFAOYSA-N
PBDE-3 C12H9BrO 4-bromodiphenyl ether 101-55-3 JDUYPUMQALQRCN-UHFFFAOYSA-N
PBDE-4 C12H8Br2O 2,2'-dibromodiphenyl ether 51452-87-0 JMSKYMHFNWGUJG-UHFFFAOYSA-N
PBDE-5 C12H8Br2O 2,3-dibromodiphenyl ether 446254-14-4 JTYRXXKXOULVAP-UHFFFAOYSA-N
PBDE-6 C12H8Br2O 2,3'-dibromodiphenyl ether 147217-72-9 GODQTPRKFHOLPH-UHFFFAOYSA-N
PBDE-7 C12H8Br2O 2,4-dibromodiphenyl ether 171977-44-9 JMCIHKKTRDLVCO-UHFFFAOYSA-N
PBDE-8 C12H8Br2O 2,4'-dibromodiphenyl ether 147217-71-8 RJQLQJZMLISKRJ-UHFFFAOYSA-N
PBDE-9 C12H8Br2O 2,5-dibromodiphenyl ether 337513-66-3 URDWJMUOJJSXAE-UHFFFAOYSA-N
PBDE-10 C12H8Br2O 2,6-dibromodiphenyl ether 51930-04-2 MUVDKHMQIZJFTC-UHFFFAOYSA-N
PBDE-11 C12H8Br2O 3,3'-dibromodiphenyl ether 6903-63-5 ALSVFJIXSNRBLE-UHFFFAOYSA-N
PBDE-12 C12H8Br2O 3,4-dibromodiphenyl ether 189084-59-1 SUUJFDKVPDCZQZ-UHFFFAOYSA-N
PBDE-13 C12H8Br2O 3,4'-dibromodiphenyl ether 83694-71-7 BGPOVBPKODCMMN-UHFFFAOYSA-N
PBDE-14 C12H8Br2O 3,5-dibromodiphenyl ether 46438-88-4 FOXBZJLXVUHYQZ-UHFFFAOYSA-N
PBDE-15 C12H8Br2O 4,4'-dibromodiphenyl ether 2050-47-7 YAWIAFUBXXPJMQ-UHFFFAOYSA-N
PBDE-16 C12H7Br3O 2,2',3-tribromodiphenyl ether 147217-74-1 VRNGWCVCSHJUEJ-UHFFFAOYSA-N
PBDE-17 C12H7Br3O 2,2',4-tribromodiphenyl ether 147217-75-2 VYBFILXLBMWOLI-UHFFFAOYSA-N
PBDE-18 C12H7Br3O 2,2',5-tribromodiphenyl ether 407606-55-7 FAZLXBWRNJAGSV-UHFFFAOYSA-N
PBDE-19 C12H7Br3O 2,2',6-tribromodiphenyl ether 147217-73-0 YDFQHBRKURQGAH-UHFFFAOYSA-N
PBDE-20 C12H7Br3O 2,3,3'-tribromodiphenyl ether 147217-76-3 RQJUBSPXDSGLRB-UHFFFAOYSA-N
PBDE-21 C12H7Br3O 2,3,4-tribromodiphenyl ether 337513-67-4 RXWRVYYPLRPDOS-UHFFFAOYSA-N
PBDE-22 C12H7Br3O 2,3,4'-tribromodiphenyl ether 446254-15-5 WZHNIFQVNBINLF-UHFFFAOYSA-N
PBDE-23 C12H7Br3O 2,3,5-tribromodiphenyl ether 446254-16-6 XQHLKDAUZRXBGC-UHFFFAOYSA-N
PBDE-24 C12H7Br3O 2,3,6-tribromodiphenyl ether 218304-36-0 GFLRHBRMAZDOIG-UHFFFAOYSA-N
PBDE-25 C12H7Br3O 2,3',4-tribromodiphenyl ether 147217-77-4 AURKEOPYVUYTLO-UHFFFAOYSA-N
PBDE-26 C12H7Br3O 2,3',5-tribromodiphenyl ether 337513-75-4 VUOBKVBAFJQQDB-UHFFFAOYSA-N
PBDE-27 C12H7Br3O 2,3',6-tribromodiphenyl ether 337513-53-8 JUPZALSVNWJHII-UHFFFAOYSA-N
PBDE-28 C12H7Br3O 2,4,4'-tribromodiphenyl ether 41318-75-6 UPNBETHEXPIWQX-UHFFFAOYSA-N
PBDE-29 C12H7Br3O 2,4,5-tribromodiphenyl ether 337513-56-1 LTMKAFUXYKEDLR-UHFFFAOYSA-N
PBDE-30 C12H7Br3O 2,4,6-tribromodiphenyl ether 155999-95-4 TVZAPPGLBLTACB-UHFFFAOYSA-N
PBDE-31 C12H7Br3O 2,4',5-tribromodiphenyl ether 65075-08-3 PURZBWMLFRWRMG-UHFFFAOYSA-N
PBDE-32 C12H7Br3O 2,4',6-tribromodiphenyl ether 189084-60-4 TYDVYKIQSZGUMV-UHFFFAOYSA-N
PBDE-33 C12H7Br3O 2,3',4'-tribromodiphenyl ether 49690-94-0 BUQBQEYUVAKJQK-UHFFFAOYSA-N
PBDE-34 C12H7Br3O 2,3',5'-tribromodiphenyl ether 446254-17-7 XMNXHCHZIPYCNA-UHFFFAOYSA-N
PBDE-35 C12H7Br3O 3,3',4-tribromodiphenyl ether 147217-80-9 CDVYKQPKJYPWRO-UHFFFAOYSA-N
PBDE-36 C12H7Br3O 3,3',5-tribromodiphenyl ether 147217-79-6 XUKPJLVONRTECE-UHFFFAOYSA-N
PBDE-37 C12H7Br3O 3,4,4'-tribromodiphenyl ether 147217-81-0 YALAYFVVZFORPV-UHFFFAOYSA-N
PBDE-38 C12H7Br3O 3,4,5-tribromodiphenyl ether 337513-54-9 DPGVQKLGQZZLMI-UHFFFAOYSA-N
PBDE-39 C12H7Br3O 3,4',5-tribromodiphenyl ether 407606-57-9 UFFNOPDHJNQYKD-UHFFFAOYSA-N
PBDE-40 C12H6Br4O 2,2',3,3'-tetrabromodiphenyl ether 337513-77-6 SXSUUFZWSVMTRL-UHFFFAOYSA-N
PBDE-41 C12H6Br4O 2,2',3,4-tetrabromodiphenyl ether 337513-68-5 UAEBSKBXZAIRMX-UHFFFAOYSA-N
PBDE-42 C12H6Br4O 2,2',3,4'-tetrabromodiphenyl ether 446254-18-8 HQDQKPAHIDGGMH-UHFFFAOYSA-N
PBDE-43 C12H6Br4O 2,2',3,5-tetrabromodiphenyl ether 446254-19-9 LKMQHSYDVDIECC-UHFFFAOYSA-N
PBDE-44 C12H6Br4O 2,2',3,5'-tetrabromodiphenyl ether 446254-20-2 VBGBGTYMDIVKNK-UHFFFAOYSA-N
PBDE-45 C12H6Br4O 2,2',3,6-tetrabromodiphenyl ether 446254-21-3 VTFWUBIOZQCMQS-UHFFFAOYSA-N
PBDE-46 C12H6Br4O 2,2',3,6'-tetrabromodiphenyl ether 446254-22-4 GBUUKJRFSKCMTB-UHFFFAOYSA-N
PBDE-47 C12H6Br4O 2,2',4,4'-tetrabromodiphenyl ether 5436-43-1 XYBSIYMGXVUVGY-UHFFFAOYSA-N
PBDE-48 C12H6Br4O 2,2',4,5-tetrabromodiphenyl ether 337513-55-0 FJGDNHOVDFREMP-UHFFFAOYSA-N
PBDE-49 C12H6Br4O 2,2',4,5'-tetrabromodiphenyl ether 243982-82-3 QWVDUBDYUPHNHY-UHFFFAOYSA-N
PBDE-50 C12H6Br4O 2,2',4,6-tetrabromodiphenyl ether 446254-23-5 FXUAKFRJBKFDSY-UHFFFAOYSA-N
PBDE-51 C12H6Br4O 2,2',4,6'-tetrabromodiphenyl ether 189084-57-9 WKBBBTLDLKYGBI-UHFFFAOYSA-N
PBDE-52 C12H6Br4O 2,2',5,5'-tetrabromodiphenyl ether 446254-24-6 CDTHXJORUCZHMD-UHFFFAOYSA-N
PBDE-53 C12H6Br4O 2,2',5,6'-tetrabromodiphenyl ether 446254-25-7 SDVQGIMOFXMKHR-UHFFFAOYSA-N
PBDE-54 C12H6Br4O 2,2',6,6'-tetrabromodiphenyl ether 446254-26-8 WCDCHQGVTZHVSO-UHFFFAOYSA-N
PBDE-55 C12H6Br4O 2,3,3',4-tetrabromodiphenyl ether 446254-27-9 VIHUMJGEWQPWOT-UHFFFAOYSA-N
PBDE-56 C12H6Br4O 2,3,3',4'-tetrabromodiphenyl ether 446254-28-0 NFOIVCGFYJIYIB-UHFFFAOYSA-N
PBDE-57 C12H6Br4O 2,3,3',5-tetrabromodiphenyl ether 337513-82-3 CSIFWDKYUJLQEB-UHFFFAOYSA-N
PBDE-58 C12H6Br4O 2,3,3',5'-tetrabromodiphenyl ether 446254-29-1 SWOYBZHGPZIRHS-UHFFFAOYSA-N
PBDE-59 C12H6Br4O 2,3,3',6-tetrabromodiphenyl ether 446254-30-4 DMAMJZQQOWYEHT-UHFFFAOYSA-N
PBDE-60 C12H6Br4O 2,3,4,4'-tetrabromodiphenyl ether 446254-31-5 ARERIMFZYPFJAV-UHFFFAOYSA-N
PBDE-61 C12H6Br4O 2,3,4,5-tetrabromodiphenyl ether 446254-32-6 NDRSXNBQWAOQPP-UHFFFAOYSA-N
PBDE-62 C12H6Br4O 2,3,4,6-tetrabromodiphenyl ether 446254-33-7 YIQYWYZZLOZVRM-UHFFFAOYSA-N
PBDE-63 C12H6Br4O 2,3,4',5-tetrabromodiphenyl ether 446254-34-8 HNICYXFGCWPYGC-UHFFFAOYSA-N
PBDE-64 C12H6Br4O 2,3,4',6-tetrabromodiphenyl ether 446254-35-9 LDCXVFJUWKKBNY-UHFFFAOYSA-N
PBDE-65 C12H6Br4O 2,3,5,6-tetrabromodiphenyl ether 446254-36-0 HPEUYVBOPJQVPN-UHFFFAOYSA-N
PBDE-66 C12H6Br4O 2,3',4,4'-tetrabromodiphenyl ether 189084-61-5 DHUMTYRHKMCVAG-UHFFFAOYSA-N
PBDE-67 C12H6Br4O 2,3',4,5-tetrabromodiphenyl ether 446254-37-1 OARGWSONVLGXQA-UHFFFAOYSA-N
PBDE-68 C12H6Br4O 2,3',4,5'-tetrabromodiphenyl ether 446254-38-2 UFWGRLCUOLLWAO-UHFFFAOYSA-N
PBDE-69 C12H6Br4O 2,3',4,6-tetrabromodiphenyl ether 327185-09-1 NHZNRCYNZJADTG-UHFFFAOYSA-N
PBDE-70 C12H6Br4O 2,3',4',5-tetrabromodiphenyl ether 446254-39-3 GHQMTYWQVJZWAR-UHFFFAOYSA-N
PBDE-71 C12H6Br4O 2,3',4',6-tetrabromodiphenyl ether 189084-62-6 COPAGYRSCJVION-UHFFFAOYSA-N
PBDE-72 C12H6Br4O 2,3',5,5'-tetrabromodiphenyl ether 446254-40-6 GBBNZKQTOOZGIS-UHFFFAOYSA-N
PBDE-73 C12H6Br4O 2,3',5',6-tetrabromodiphenyl ether 446254-41-7 WQFLVWXBCRJAQN-UHFFFAOYSA-N
PBDE-74 C12H6Br4O 2,4,4',5-tetrabromodiphenyl ether 446254-42-8 LXCFDVVDUVPAGR-UHFFFAOYSA-N
PBDE-75 C12H6Br4O 2,4,4',6-tetrabromodiphenyl ether 189084-63-7 BWCNKMFFUGBFGB-UHFFFAOYSA-N
PBDE-76 C12H6Br4O 2,3',4',5'-tetrabromodiphenyl ether 446254-43-9 NCSWBJSFVPJPPK-UHFFFAOYSA-N
PBDE-77 C12H6Br4O 3,3',4,4'-tetrabromodiphenyl ether 93703-48-1 RYGLOWMCGZHYRQ-UHFFFAOYSA-N
PBDE-78 C12H6Br4O 3,3',4,5-tetrabromodiphenyl ether 446254-45-1 HWOBLTZZSVXBOJ-UHFFFAOYSA-N
PBDE-79 C12H6Br4O 3,3',4,5'-tetrabromodiphenyl ether 446254-48-4 LELQGHJEUVRPEV-UHFFFAOYSA-N
PBDE-80 C12H6Br4O 3,3',5,5'-tetrabromodiphenyl ether 103173-66-6 HFIOZJQRZKNPKJ-UHFFFAOYSA-N
PBDE-81 C12H6Br4O 3,4,4',5-tetrabromodiphenyl ether 446254-50-8 ULFOIXCXIWHJDS-UHFFFAOYSA-N
PBDE-82 C12H5Br5O 2,2',3,3',4-pentabromodiphenyl ether 327185-11-5 RQMSPGJESCCPQX-UHFFFAOYSA-N
PBDE-83 C12H5Br5O 2,2',3,3',5-pentabromodiphenyl ether 446254-51-9 XAHYSNUYJLNDBX-UHFFFAOYSA-N
PBDE-84 C12H5Br5O 2,2',3,3',6-pentabromodiphenyl ether 446254-52-0 PPIZNRAVQHNLJM-UHFFFAOYSA-N
PBDE-85 C12H5Br5O 2,2',3,4,4'-pentabromodiphenyl ether 182346-21-0 DMLQSUZPTTUUDP-UHFFFAOYSA-N
PBDE-86 C12H5Br5O 2,2',3,4,5-pentabromodiphenyl ether 446254-53-1 YMVWYUWOUOQCQP-UHFFFAOYSA-N
PBDE-87 C12H5Br5O 2,2',3,4,5'-pentabromodiphenyl ether 446254-54-2 WKYQUGCIKNOXFW-UHFFFAOYSA-N
PBDE-88 C12H5Br5O 2,2',3,4,6-pentabromodiphenyl ether 446254-55-3 OPZUHBCVIZNZFB-UHFFFAOYSA-N
PBDE-89 C12H5Br5O 2,2',3,4,6'-pentabromodiphenyl ether 446254-56-4 XGFLJLJXVIMCNR-UHFFFAOYSA-N
PBDE-90 C12H5Br5O 2,2',3,4',5-pentabromodiphenyl ether 446254-57-5 BATFXMGTVIESIQ-UHFFFAOYSA-N
PBDE-91 C12H5Br5O 2,2',3,4',6-pentabromodiphenyl ether 446254-58-6 HWNJTZKDPNZUSO-UHFFFAOYSA-N
PBDE-92 C12H5Br5O 2,2',3,5,5'-pentabromodiphenyl ether 446254-59-7 QWSQOVAGRDRZLM-UHFFFAOYSA-N
PBDE-93 C12H5Br5O 2,2',3,5,6-pentabromodiphenyl ether 446254-60-0 BRTPVPJQMWLDNO-UHFFFAOYSA-N
PBDE-94 C12H5Br5O 2,2',3,5,6'-pentabromodiphenyl ether 446254-61-1 JOPASNJHCFYVHD-UHFFFAOYSA-N
PBDE-95 C12H5Br5O 2,2',3,5',6-pentabromodiphenyl ether 446254-62-2 BZDYRALIEYVMEP-UHFFFAOYSA-N
PBDE-96 C12H5Br5O 2,2',3,6,6'-pentabromodiphenyl ether 446254-63-3 ZFCJNRDWGBZUED-UHFFFAOYSA-N
PBDE-97 C12H5Br5O 2,2',3,4',5'-pentabromodiphenyl ether 446254-64-4 MAGYDGJRSCULJL-UHFFFAOYSA-N
PBDE-98 C12H5Br5O 2,2',3,4',6'-pentabromodiphenyl ether 38463-82-0 OCLWEJVGAUFXQU-UHFFFAOYSA-N
PBDE-99 C12H5Br5O 2,2',4,4',5-pentabromodiphenyl ether 60348-60-9 WHPVYXDFIXRKLN-UHFFFAOYSA-N
PBDE-100 C12H5Br5O 2,2',4,4',6-pentabromodiphenyl ether 189084-64-8 NSKIRYMHNFTRLR-UHFFFAOYSA-N
PBDE-101 C12H5Br5O 2,2',4,5,5'-pentabromodiphenyl ether 446254-65-5 QUZWDWNIWWAQDI-UHFFFAOYSA-N
PBDE-102 C12H5Br5O 2,2',4,5,6'-pentabromodiphenyl ether 446254-66-6 JHFMCUVMAIQWRI-UHFFFAOYSA-N
PBDE-103 C12H5Br5O 2,2',4,5',6-pentabromodiphenyl ether 446254-67-7 RJEMKRNASVHYKR-UHFFFAOYSA-N
PBDE-104 C12H5Br5O 2,2',4,6,6'-pentabromodiphenyl ether 446254-68-8 CRSCWEYUPUKHPI-UHFFFAOYSA-N
PBDE-105 C12H5Br5O 2,3,3',4,4'-pentabromodiphenyl ether 373594-78-6 LBPWAGZGYNOKAM-UHFFFAOYSA-N
PBDE-106 C12H5Br5O 2,3,3',4,5-pentabromodiphenyl ether 446254-69-9 KLQKWMYXEWUAFP-UHFFFAOYSA-N
PBDE-107 C12H5Br5O 2,3,3',4',5-pentabromodiphenyl ether 446254-70-2 OMGVAMFMRSETEG-UHFFFAOYSA-N
PBDE-108 C12H5Br5O 2,3,3',4,5'-pentabromodiphenyl ether 446254-71-3 VBKPKHVLHGOKOJ-UHFFFAOYSA-N
PBDE-109 C12H5Br5O 2,3,3',4,6-pentabromodiphenyl ether 446254-72-4 FXXXWTMLIQLDRP-UHFFFAOYSA-N
PBDE-110 C12H5Br5O 2,3,3',4',6-pentabromodiphenyl ether 446254-73-5 LESZGJVTZILBTK-UHFFFAOYSA-N
PBDE-111 C12H5Br5O 2,3,3',5,5'-pentabromodiphenyl ether 446254-74-6 PCHDCOXHJBWEPW-UHFFFAOYSA-N
PBDE-112 C12H5Br5O 2,3,3',5,6-pentabromodiphenyl ether 446254-75-7 MFBMNSFADPTAKZ-UHFFFAOYSA-N
PBDE-113 C12H5Br5O 2,3,3',5',6-pentabromodiphenyl ether 446254-76-8 OGZHLJXRGZFVLI-UHFFFAOYSA-N
PBDE-114 C12H5Br5O 2,3,4,4',5-pentabromodiphenyl ether 446254-77-9 SFNAUTSNWPPDSY-UHFFFAOYSA-N
PBDE-115 C12H5Br5O 2,3,4,4',6-pentabromodiphenyl ether 446254-78-0 BKTLDVXDOVSTEV-UHFFFAOYSA-N
PBDE-116 C12H5Br5O 2,3,4,5,6-pentabromodiphenyl ether 189084-65-9 ACRQLFSHISNWRY-UHFFFAOYSA-N
PBDE-117 C12H5Br5O 2,3,4',5,6-pentabromodiphenyl ether 446254-79-1 SOJBOGWFDBDWEG-UHFFFAOYSA-N
PBDE-118 C12H5Br5O 2,3',4,4',5-pentabromodiphenyl ether 446254-80-4 VTMFEPLDDHZBGI-UHFFFAOYSA-N
PBDE-119 C12H5Br5O 2,3',4,4',6-pentabromodiphenyl ether 189084-66-0 KXEOYBYEJCRPGB-UHFFFAOYSA-N
PBDE-120 C12H5Br5O 2,3',4,5,5'-pentabromodiphenyl ether 417727-71-0 AKSBEUHDCRZJAN-UHFFFAOYSA-N
PBDE-121 C12H5Br5O 2,3',4,5',6-pentabromodiphenyl ether 446254-81-5 GVGNVZBJVFDAAO-UHFFFAOYSA-N
PBDE-122 C12H5Br5O 2,3,3',4',5'-pentabromodiphenyl ether 446254-82-6 CDNHGSPFIUITTN-UHFFFAOYSA-N
PBDE-123 C12H5Br5O 2,3',4,4',5'-pentabromodiphenyl ether 446254-83-7 SBKMUEQNZNDYFW-UHFFFAOYSA-N
PBDE-124 C12H5Br5O 2,3',4',5,5'-pentabromodiphenyl ether 446254-84-8 FGHJTAAHIFEHLT-UHFFFAOYSA-N
PBDE-125 C12H5Br5O 2,3',4',5',6-pentabromodiphenyl ether 446254-85-9 SESXKFPOVUVGLR-UHFFFAOYSA-N
PBDE-126 C12H5Br5O 3,3',4,4',5-pentabromodiphenyl ether 366791-32-4 SJNIIWPIAVQNRK-UHFFFAOYSA-N
PBDE-127 C12H5Br5O 3,3',4,5,5'-pentabromodiphenyl ether 446254-86-0 RATMRXKBPDCKCZ-UHFFFAOYSA-N
PBDE-128 C12H4Br6O 2,2',3,3',4,4'-hexabromodiphenyl ether 182677-28-7 WFLVELCLEGVBIH-UHFFFAOYSA-N
PBDE-129 C12H4Br6O 2,2',3,3',4,5-hexabromodiphenyl ether 446254-87-1 PRNCVYAUCSGSOE-UHFFFAOYSA-N
PBDE-130 C12H4Br6O 2,2',3,3',4,5'-hexabromodiphenyl ether 446254-88-2 YURCHLXPAGSJHU-UHFFFAOYSA-N
PBDE-131 C12H4Br6O 2,2',3,3',4,6-hexabromodiphenyl ether 446254-89-3 MGKVPJFIGGBCBA-UHFFFAOYSA-N
PBDE-132 C12H4Br6O 2,2',3,3',4,6'-hexabromodiphenyl ether 446254-90-6 FFEKBOKDYRZGRV-UHFFFAOYSA-N
PBDE-133 C12H4Br6O 2,2',3,3',5,5'-hexabromodiphenyl ether 446254-91-7 XTBFPFHQPGZZJX-UHFFFAOYSA-N
PBDE-134 C12H4Br6O 2,2',3,3',5,6-hexabromodiphenyl ether 446254-92-8 MIBDGPWSGDWIQR-UHFFFAOYSA-N
PBDE-135 C12H4Br6O 2,2',3,3',5,6'-hexabromodiphenyl ether 446254-93-9 AMGHASDTWACNCS-UHFFFAOYSA-N
PBDE-136 C12H4Br6O 2,2',3,3',6,6'-hexabromodiphenyl ether 446254-94-0 NTWGDSLWLUPCDW-UHFFFAOYSA-N
PBDE-137 C12H4Br6O 2,2',3,4,4',5-hexabromodiphenyl ether 446254-95-1 HSTYYNPYXZYIAG-UHFFFAOYSA-N
PBDE-138 C12H4Br6O 2,2',3,4,4',5'-hexabromodiphenyl ether 182677-30-1 IZFQCEZFGCMHOM-UHFFFAOYSA-N
PBDE-139 C12H4Br6O 2,2',3,4,4',6-hexabromodiphenyl ether 446254-96-2 YESDYWNWEVPOLZ-UHFFFAOYSA-N
PBDE-140 C12H4Br6O 2,2',3,4,4',6'-hexabromodiphenyl ether 243982-83-4 FLRODCDHJZNIGA-UHFFFAOYSA-N
PBDE-141 C12H4Br6O 2,2',3,4,5,5'-hexabromodiphenyl ether 446254-97-3 XTXIYMGRRUJOIT-UHFFFAOYSA-N
PBDE-142 C12H4Br6O 2,2',3,4,5,6-hexabromodiphenyl ether 446254-98-4 LJDGJCNHVGGOFW-UHFFFAOYSA-N
PBDE-143 C12H4Br6O 2,2',3,4,5,6'-hexabromodiphenyl ether 446254-99-5 RQLZDUSZXOOBTM-UHFFFAOYSA-N
PBDE-144 C12H4Br6O 2,2',3,4,5',6-hexabromodiphenyl ether 446255-00-1 ZMSJCQOCTPYCQP-UHFFFAOYSA-N
PBDE-145 C12H4Br6O 2,2',3,4,6,6'-hexabromodiphenyl ether 446255-01-2 BTKLHMBWCRVCLC-UHFFFAOYSA-N
PBDE-146 C12H4Br6O 2,2',3,4',5,5'-hexabromodiphenyl ether 446255-02-3 HGXPYDNHBUCRTR-UHFFFAOYSA-N
PBDE-147 C12H4Br6O 2,2',3,4',5,6-hexabromodiphenyl ether 116995-33-6 OWBKWMDBTWHGHS-UHFFFAOYSA-N
PBDE-148 C12H4Br6O 2,2',3,4',5,6'-hexabromodiphenyl ether 446255-03-4 OJMHGSMSQZEBFH-UHFFFAOYSA-N
PBDE-149 C12H4Br6O 2,2',3,4',5',6-hexabromodiphenyl ether 446255-04-5 UJOUSZKYGGTPFQ-UHFFFAOYSA-N
PBDE-150 C12H4Br6O 2,2',3,4',6,6'-hexabromodiphenyl ether 446255-05-6 SQNOZOVDXXSLSG-UHFFFAOYSA-N
PBDE-151 C12H4Br6O 2,2',3,5,5',6-hexabromodiphenyl ether 446255-06-7 NGOQQUYCSISZMY-UHFFFAOYSA-N
PBDE-152 C12H4Br6O 2,2',3,5,6,6'-hexabromodiphenyl ether 446255-07-8 BYBJJARTBKUIJD-UHFFFAOYSA-N
PBDE-153 C12H4Br6O 2,2',4,4',5,5'-hexabromodiphenyl ether 68631-49-2 RZXIRSKYBISPGF-UHFFFAOYSA-N
PBDE-154 C12H4Br6O 2,2',4,4',5,6'-hexabromodiphenyl ether 207122-15-4 VHNPZYZQKWIWOD-UHFFFAOYSA-N
PBDE-155 C12H4Br6O 2,2',4,4',6,6'-hexabromodiphenyl ether 35854-94-5 HRSCBOSGEKXXSI-UHFFFAOYSA-N
PBDE-156 C12H4Br6O 2,3,3',4,4',5-hexabromodiphenyl ether 405237-85-6 JSDPCMJWYRDQEV-UHFFFAOYSA-N
PBDE-157 C12H4Br6O 2,3,3',4,4',5'-hexabromodiphenyl ether 446255-08-9 JUOAMVUIJQJZSZ-UHFFFAOYSA-N
PBDE-158 C12H4Br6O 2,3,3',4,4',6-hexabromodiphenyl ether 446255-09-0 KRYHHTVQOOJNHQ-UHFFFAOYSA-N
PBDE-159 C12H4Br6O 2,3,3',4,5,5'-hexabromodiphenyl ether 446255-10-3 IDYFFNCFLRCOPZ-UHFFFAOYSA-N
PBDE-160 C12H4Br6O 2,3,3',4,5,6-hexabromodiphenyl ether 446255-11-4 OCVOYHGOXIIONK-UHFFFAOYSA-N
PBDE-161 C12H4Br6O 2,3,3',4,5',6-hexabromodiphenyl ether 446255-12-5 WEYWRBBPPKSRGU-UHFFFAOYSA-N
PBDE-162 C12H4Br6O 2,3,3',4',5,5'-hexabromodiphenyl ether 446255-13-6 UKPNCLHMNJCGCJ-UHFFFAOYSA-N
PBDE-163 C12H4Br6O 2,3,3',4',5,6-hexabromodiphenyl ether 446255-14-7 NUEAHMLXQFHEJN-UHFFFAOYSA-N
PBDE-164 C12H4Br6O 2,3,3',4',5',6-hexabromodiphenyl ether 446255-15-8 UJVYVXIHTJOJBZ-UHFFFAOYSA-N
PBDE-165 C12H4Br6O 2,3,3',5,5',6-hexabromodiphenyl ether 446255-16-9 KXERERDGMTWBGZ-UHFFFAOYSA-N
PBDE-166 C12H4Br6O 2,3,4,4',5,6-hexabromodiphenyl ether 189084-58-0 KVYODBMKQYVNEK-UHFFFAOYSA-N
PBDE-167 C12H4Br6O 2,3',4,4',5,5'-hexabromodiphenyl ether 446255-17-0 NMUPLZRHSXJCJQ-UHFFFAOYSA-N
PBDE-168 C12H4Br6O 2,3',4,4',5',6-hexabromodiphenyl ether 53551-87-4 HWZAPXGFMVEGPW-UHFFFAOYSA-N
PBDE-169 C12H4Br6O 3,3',4,4',5,5'-hexabromodiphenyl ether 446255-18-1 JKFBMDHBJYKFKL-UHFFFAOYSA-N
PBDE-170 C12H3Br7O 2,2',3,3',4,4',5-heptabromodiphenyl ether 327185-13-7 DLPNCMQTNWLTHD-UHFFFAOYSA-N
PBDE-171 C12H3Br7O 2,2',3,3',4,4',6-heptabromodiphenyl ether 446255-19-2 FRMMMROUUPQUMZ-UHFFFAOYSA-N
PBDE-172 C12H3Br7O 2,2',3,3',4,5,5'-heptabromodiphenyl ether 407606-59-1 DSRRSKFMOJQETR-UHFFFAOYSA-N
PBDE-173 C12H3Br7O 2,2',3,3',4,5,6-heptabromodiphenyl ether 446255-20-5 NLBLNZDNOSSGPW-UHFFFAOYSA-N
PBDE-174 C12H3Br7O 2,2',3,3',4,5,6'-heptabromodiphenyl ether 446255-21-6 VUUWOHUOYUGBEO-UHFFFAOYSA-N
PBDE-175 C12H3Br7O 2,2',3,3',4,5',6-heptabromodiphenyl ether 6255-22-7 YATZWTXATDYQCK-UHFFFAOYSA-N
PBDE-176 C12H3Br7O 2,2',3,3',4,6,6'-heptabromodiphenyl ether 407606-61-5 SWUALKCOTZOSMY-UHFFFAOYSA-N
PBDE-177 C12H3Br7O 2,2',3,3',4,5',6'-heptabromodiphenyl ether 446255-23-8 ZHUHLPXIJIBQBJ-UHFFFAOYSA-N
PBDE-178 C12H3Br7O 2,2',3,3',5,5',6-heptabromodiphenyl ether 446255-24-9 UWUVZUPEEORCRG-UHFFFAOYSA-N
PBDE-179 C12H3Br7O 2,2',3,3',5,6,6'-heptabromodiphenyl ether 446255-25-0 COVXWWKOLMNRQE-UHFFFAOYSA-N
PBDE-180 C12H3Br7O 2,2',3,4,4',5,5'-heptabromodiphenyl ether 446255-26-1 STMBXVOJNOJRPZ-UHFFFAOYSA-N
PBDE-181 C12H3Br7O 2,2',3,4,4',5,6-heptabromodiphenyl ether 189084-67-1 GVNRIAPLVGNZPL-UHFFFAOYSA-N
PBDE-182 C12H3Br7O 2,2',3,4,4',5,6'-heptabromodiphenyl ether 442690-45-1 ZYHDTADADSNMLV-UHFFFAOYSA-N
PBDE-183 C12H3Br7O 2,2',3,4,4',5',6-heptabromodiphenyl ether 207122-16-5 ILPSCQCLBHQUEM-UHFFFAOYSA-N
PBDE-184 C12H3Br7O 2,2',3,4,4',6,6'-heptabromodiphenyl ether 117948-63-7 JHDCZVAQPRXHEL-UHFFFAOYSA-N
PBDE-185 C12H3Br7O 2,2',3,4,5,5',6-heptabromodiphenyl ether 405237-86-7 YRNMIFAQDSUFTR-UHFFFAOYSA-N
PBDE-186 C12H3Br7O 2,2',3,4,5,6,6'-heptabromodiphenyl ether 446255-27-2 WUFQDCMRKKDNSF-UHFFFAOYSA-N
PBDE-187 C12H3Br7O 2,2',3,4',5,5',6-heptabromodiphenyl ether 446255-28-3 RFZPXOBFDARWHV-UHFFFAOYSA-N
PBDE-188 C12H3Br7O 2,2',3,4',5,6,6'-heptabromodiphenyl ether 116995-32-5 YGYDHFDPVGAMTL-UHFFFAOYSA-N
PBDE-189 C12H3Br7O 2,3,3',4,4',5,5'-heptabromodiphenyl ether 259087-35-9 CQVLRTUESBMMJW-UHFFFAOYSA-N
PBDE-190 C12H3Br7O 2,3,3',4,4',5,6-heptabromodiphenyl ether 189084-68-2 OUEYHQIMJGHOQN-UHFFFAOYSA-N
PBDE-191 C12H3Br7O 2,3,3',4,4',5',6-heptabromodiphenyl ether 446255-30-7 BNBFKFHSIPERIM-UHFFFAOYSA-N
PBDE-192 C12H3Br7O 2,3,3',4,5,5',6-heptabromodiphenyl ether 407578-53-4 ABLZOLAUBUSUHT-UHFFFAOYSA-N
PBDE-193 C12H3Br7O 2,3,3',4',5,5',6-heptabromodiphenyl ether 446255-34-1 AUFJSWANTKXCFZ-UHFFFAOYSA-N
PBDE-194 C12H2Br8O 2,2',3,3',4,4',5,5'-octabromodiphenyl ether 32536-52-0 ORYGKUIDIMIRNN-UHFFFAOYSA-N
PBDE-195 C12H2Br8O 2,2',3,3',4,4',5,6-octabromodiphenyl ether 446255-38-5 GPQLSLKPHQEEOP-UHFFFAOYSA-N
PBDE-196 C12H2Br8O 2,2',3,3',4,4',5,6'-octabromodiphenyl ether 446255-39-6 IEWFKOVTVJNWFF-UHFFFAOYSA-N
PBDE-197 C12H2Br8O 2,2',3,3',4,4',6,6'-octabromodiphenyl ether 117964-21-3 AAFUUKPTSPVXJH-UHFFFAOYSA-N
PBDE-198 C12H2Br8O 2,2',3,3',4,5,5',6-octabromodiphenyl ether 446255-42-1 IBKRHVDFFHQOSC-UHFFFAOYSA-N
PBDE-199 C12H2Br8O 2,2',3,3',4,5,5',6'-octabromodiphenyl ether 446255-43-2 JNSLJYRXDGBNBE-UHFFFAOYSA-N
PBDE-200 C12H2Br8O 2,2',3,3',4,5,6,6'-octabromodiphenyl ether 446255-46-5 JWMXGEPFVCRXQR-UHFFFAOYSA-N
PBDE-201 C12H2Br8O 2,2',3,3',4,5',6,6'-octabromodiphenyl ether 446255-50-1 HQWFMMKREWXIGN-UHFFFAOYSA-N
PBDE-202 C12H2Br8O 2,2',3,3',5,5',6,6'-octabromodiphenyl ether 67797-09-5 AHNZLQAZTWRRDW-UHFFFAOYSA-N
PBDE-203 C12H2Br8O 2,2',3,4,4',5,5',6-octabromodiphenyl ether 337513-72-1 RTUZOQFRIPIWPS-UHFFFAOYSA-N
PBDE-204 C12H2Br8O 2,2',3,4,4',5,6,6'-octabromodiphenyl ether 446255-54-5 YZABCBOJTHQTSX-UHFFFAOYSA-N
PBDE-205 C12H2Br8O 2,3,3',4,4',5,5',6-octabromodiphenyl ether 446255-56-7 CVMKCYDBEYHNBM-UHFFFAOYSA-N
PBDE-206 C12HBr9O 2,2',3,3',4,4',5,5',6-nonabromodiphenyl ether 63387-28-0 CYRHBNRLQMLULE-UHFFFAOYSA-N
PBDE-207 C12HBr9O 2,2',3,3',4,4',5,6,6'-nonabromodiphenyl ether 437701-79-6 IEEVDIAVLGLVOW-UHFFFAOYSA-N
PBDE-208 C12HBr9O 2,2',3,3',4,5,5',6,6'-nonabromodiphenyl ether 437701-78-5 ASGZXYIDLFWXID-UHFFFAOYSA-N
PBDE-209 C12Br10O decabromodiphenyl ether 1163-19-5 WHHGLZMJPXIBIX-UHFFFAOYSA-N

Production

[edit]

PBDEs were produced commercially via the bromination of diphenyl ether,[8] with three technical-grade mixtures being sold, varying by degree of bromination.

In the United States, PBDEs were marketed with the trade names DE-60F, DE-61, DE-62, and DE-71 applied to pentaBDE mixtures, DE-79 applied to octaBDE mixtures, and DE 83R and Saytex 102E applied to decaBDE mixtures. The available commercial PBDE products were not single compounds or even single congeners but rather mixtures of congeners.

Technical pentaBDE predominantly contained pentabromo derivatives (50–62%); however, the mixture also contained tetrabromides (24–38%) and hexabromides (4–8%), as well as traces of the tribromides (0–1%). Technical octaBDE was a mixture of homologs: hexa-, hepta-, octa-, nona-, and decabromides. Technical decaBDE was 97% decabromide, with small amounts of octa- and nonabromides.[7]

Commercial production of PBDEs began in the 1970s,[9] and continued until the early 2010s. Cumulative global production is estimated to have been 175 kt for pentaBDE, 130 kt for octaBDE, and 1600 kt for decaBDE.[10]

Health and environmental concerns

[edit]

Exposure

[edit]

Polybrominated diphenyl ethers (PBDEs) can be released into the environment where they are used or produced, possibly entering air, water, soil or the human digestive system when consumed, inhaled or via the skin.[11][12] Despite the banning and phase out of several forms of PBDEs, many consumer products still contain them in the 21st century, and represent potential exposure sources, including furniture and other consumer products containing polyurethane foam, appliances, pipes, plastics, and old electronic equipment.[11][13]

Generally, governments have determined that PBDEs are not harmful to human health in the exposure amounts assessed.[11][12][14] Ingestion of house dust accounts for 80–90% of total PBDE exposure, while the remaining exposure occurs from food ingestion.[11][12] PBDE-contaminated foods, particularly those high in fat content, such as fatty meats or fish, are possible sources of exposure.[11] In breastfeeding infants, breast milk may be an exposure source because PBDEs can be present in the mother and her milk.[11] Various other food items may contain PBDEs, including meat, meat products, dairy products, and seafood.[11][14]

PBDEs have not been detected beyond trace levels in water.[11] In the environment, soils and sediments are the major deposits for PBDEs.[11] PBDEs can enter soil from discarded products, such as in landfills. As biosolids (sewage) may contain PBDEs, exposure from soils or farmlands that have been fertilized with biosolids may occur.[11] Wildlife may have exposure by consuming foods containing PBDEs, whereas organisms that live in sediments may be contaminated by PBDEs.[12]

Excretion

[edit]

PBDEs and their metabolites are excreted mainly in the feces and some in the urine.[11] Owing to their deposition in body fat stores, some PBDEs remain in the body for many years, and may enter the bodies of unborn babies via the placenta.[11]

Research on health effects

[edit]

Nothing certain has been established about the effects of PBDEs on human health.[11][12][14] Most information regarding toxicity of PBDEs and their metabolites is from early-stage animal studies.[14] Evidence for PBDE-mediated effects from human studies in systems other than the developing nervous system, such as in cancer development, is inconclusive or non-existent.[11] Particularly for the potential effects of PBDEs on the developing fetus, research has focused on the health status of mothers and gestational age of the infant.[15]

Sediment contamination

[edit]

Increasing environmental concentrations and changing distributions of PBDEs in sediments of the Clyde River Estuary in Scotland, UK have been assessed.[16] Analysis of six sediment cores each of 1 m depth from Glasgow city to Greenock revealed that total concentrations increased toward the river bed surface (0–10 cm). Amounts of PBDE ranged from 1 to 2,645 µg/kg (dry wt. sediment) with a mean of 287 µg/kg (dry wt. sediment).[16] Down-core PBDE congener profiles showed that higher concentrations were due to elevated levels of BDE-209. The majority of the sediment records clearly showed a change from mainly lower molecular weight BDEs 47,99, 183, 153 at lower depths to BDE-209 near the surface, a change in congener and homologue group patterns that corresponds to the restrictions of penta- and octaBDE commercial mixtures under EU law in 2004–2006.

While biodegradation is not considered the main pathway for PBDEs, photolysis and pyrolysis can be of interest in studies of transformation of PBDEs.[17][18]

Regulations of PBDEs

[edit]

United States

[edit]

In August 2003, the State of California outlawed the sale of penta- and octaBDE and products containing them, effective 1 January 2008.[19] PBDEs are ubiquitous in the environment, and, according to the EPA, exposure may pose health risks. According to U.S. EPA's Integrated Risk Information System, evidence indicates that PBDEs may possess liver toxicity, thyroid toxicity, and neurodevelopmental toxicity.[20][21] In June 2008, the U.S. EPA set a safe daily exposure level ranging from 0.1 to 7 μg/kg body weight per day for the four most common PBDE congeners.[20][21][22][23] In April 2007, the legislature of the state of Washington passed a bill banning the use of PBDEs.[24] The State of Maine Department of Environmental Protection has restrictions on PBDEs, and in 2008, the legislature passed a bill phasing out the use of decaBDE.[25]

The U.S. importers and manufacturers of PBDEs withdrew pentaBDE and octaBDE from sale in 2004, and decaBDE from sale by the end of 2013.[7]: 10 [26] In November 2024, the EPA added decaBDE to the Toxic Substances Control Act to prohibit release into water during manufacturing, processing or distribution in commerce of decaBDE and decaBDE-containing products, and a phase-out of processing and distribution of wire and cable insulation containing decaDBE for nuclear power facilities.[27]

Canada

[edit]

Since 2012, PBDEs are among chemicals prohibited from manufacture, use, sale, offer for sale or import, as regulated in the Prohibition of Certain Toxic Substances Regulations of the 1999 Canadian Environmental Protection Act.[28] PBDEs are regarded in the regulation as "toxic to the environment and/or human health, are generally persistent, bioaccumulative, and/or inherently toxic."[28]

European Union

[edit]

The European Union decided to ban the use of two classes of flame retardants, in particular, PBDEs and polybrominated biphenyls (PBBs) in electric and electronic devices.[13] This ban was formalised in the RoHS Directive, and an upper limit of 1 g/kg for the sum of PBBs and PBDEs was set. In February 2009, the Institute for Reference Materials and Measurements released two certified reference materials to help analytical laboratories better detect these two classes of flame retardants. The reference materials were custom-made to contain all relevant PBDEs and PBBs at levels close to the legal limit.[13]

International

[edit]

At an international level, in May 2009 the Parties of the Stockholm Convention on Persistent Organic Pollutants (POPs) decided to list commercial pentaBDE and commercial octaBDE as POP substances. This listing is due to the properties of hexaBDE and heptaBDE, which are components of commercial octaBDE, and to the properties of tetraBDE and pentaBDE, which are the main components of commercial pentaBDE.[29] In 2017, it was decided to also list decaBDE.[4][30]

Alternatives

[edit]

Major decaBDE producers have switched to manufacturing decabromodiphenyl ethane, a structurally related compound that has also come under suspicion as an environmental pollutant.[2]: 21  Non-halogenated alternatives also exist.[2][26]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Polybrominated s (PBDEs) are a class of synthetic organobromine chemicals comprising two phenyl rings connected by an oxygen atom, substituted with two to ten atoms across 209 possible congeners, commercially formulated into mixtures such as pentaBDE, octaBDE, and decaBDE for use as additive retardants. These compounds are incorporated into polymers, foams, textiles, and electronic casings to inhibit ignition and slow spread, thereby enhancing in consumer and industrial products. Unlike reactive flame retardants that chemically bond to host materials, PBDEs' additive application results in gradual leaching, contributing to their widespread environmental dispersal. PBDEs exhibit high in the environment, resisting degradation and bioaccumulating in lipid-rich tissues through trophic in food webs, with lower-brominated congeners demonstrating greater uptake efficiency. studies have documented toxicological effects including thyroid hormone disruption, neurodevelopmental impairments, and reproductive alterations in and , prompting scrutiny of human health risks despite epidemiological associations remaining correlative rather than conclusively causal. Regulatory responses include voluntary phase-outs by U.S. manufacturers by 2004 for penta- and octaBDE formulations, marketing bans on these mixtures since 2004 under REACH, and subsequent restrictions on decaBDE, correlating with observed declines in serum concentrations, though legacy sources sustain ongoing exposure via and dietary . Global emissions from historical stocks continue to influence environmental levels, underscoring challenges in eliminating persistent additives despite substitution efforts.

Chemical Properties and Classes

Molecular Structure and Nomenclature

Polybrominated diphenyl ethers (PBDEs) are organo compounds featuring two phenyl rings linked by an (oxygen) bridge, with atoms substituting for atoms on the aromatic rings. The general molecular is C₁₂H_{10-n}Br_nO, where n represents the number of atoms, typically ranging from 2 to 10, yielding 209 possible congeners due to varying positions of substitution on the rings. This structure resembles polychlorinated biphenyls (PCBs) but incorporates an linkage instead of a biphenyl bond, influencing their and environmental behavior. PBDEs are categorized by bromination degree into classes such as tetra-BDEs, penta-BDEs, hexa-BDEs, and up to deca-BDEs, with commercial formulations often dominated by mixtures of specific homologues. Individual congeners receive unique identifiers using the Ballschmiter-Zell numbering system, developed in 1980, which sequences them in ascending order based on count and substitution patterns, denoted as BDE-number (e.g., BDE-47 for 2,2',4,4'-tetrabromodiphenyl , BDE-99 for 2,2',4,4',5-pentabromodiphenyl ). This IUPAC-compatible standardizes reporting in toxicological and analytical contexts, enabling precise tracking of dominant environmental contaminants like BDE-47 and BDE-209. The positional isomers arise from bromine attachments at ortho, meta, or para sites relative to the oxygen, with symmetric and asymmetric configurations affecting properties like and ; for instance, fully brominated deca-BDE (BDE-209) exhibits lower volatility compared to tetra-BDEs. Systematic naming follows conventions, specifying bromine locants (e.g., 2,2',4,4'-tetrabromo-1,1'-oxybisbenzene).

Commercial Mixtures and Congeners

Commercial polybrominated diphenyl ethers (PBDEs) were produced and sold as technical mixtures containing multiple congeners, rather than isolated compounds, due to the synthetic processes yielding complex compositions. The primary formulations included pentaBDE, octaBDE, and decaBDE mixtures, each dominated by specific bromination levels and key congeners identified through gas chromatography-mass spectrometry analyses. Up to 39 discrete PBDE congeners have been detected across these mixtures. PentaBDE mixtures, such as DE-71 (Great Lakes Chemical) and Bromkal 70-5DE (Bromine Compounds Ltd.), comprised mainly tetrabrominated (24–38%), pentabrominated (50–62%), and hexabrominated (4–8%) diphenyl ethers, with trace tribrominated species. Dominant congeners were BDE-47 (25–37%), BDE-99 (35–50%), and BDE-100 (6–10%), alongside lesser amounts of BDE-153, BDE-154, and others like BDE-28, BDE-66, and BDE-183. OctaBDE products, exemplified by DE-79 (Great Lakes Chemical), featured predominantly hepta- and octabrominated congeners, with contributions from hexa- and nonabrominated homologues and trace decabrominated BDE-209. Key congeners included BDE-183 (approximately 40%), BDE-197 (21%), BDE-196 (8%), and BDE-203 (5–35%), as well as BDE-153 and BDE-154. DecaBDE mixtures, such as DE-83R (Great Lakes Chemical) and Saytex 102E (Albemarle), were primarily BDE-209 (97–97.5%), with the balance consisting of nonabrominated congeners BDE-206, BDE-207, and BDE-208, plus minor octabrominated impurities.
MixtureMajor Congeners (% where specified)Homologue Focus
PentaBDEBDE-47 (25–37%), BDE-99 (35–50%), BDE-100 (6–10%)Tetra-, penta-, hexaBDE
OctaBDEBDE-183 (~40%), BDE-197 (21%), BDE-196 (8%)Hexa-, hepta-, octa-, nonaBDE
DecaBDEBDE-209 (97–97.5%), BDE-206/207/208 (remainder)DecaBDE, nonaBDE

History and Production

Early Development and Commercialization

Polybrominated diphenyl ethers (PBDEs) emerged as synthetic additive flame retardants during the , designed to imbue polymers with enhanced resistance to ignition and flame spread without excessive volatility or migration from host materials. These compounds were synthesized by brominating through stepwise addition of atoms, yielding congeners with varying degrees of substitution (from mono- to deca-brominated forms), which were then formulated into technical mixtures for industrial application. Early efforts focused on tetra- through octa-brominated variants for their balance of efficacy and processability in plastics and foams, supplanting prior brominated alternatives like polybrominated biphenyls (PBBs) that had demonstrated instability in some uses. Commercial production scaled up in the late , primarily by U.S.-based firms such as Great Lakes Chemical Corporation (manufacturer of DE-60F for octaBDE, DE-71 for pentaBDE, and DE-83R for decaBDE) and (formerly ), which together dominated North American output and accounted for nearly all global supply until the 1990s. These mixtures, containing 30–68% by weight, were marketed for their cost-effectiveness and compatibility with polyurethane flexible foams, high-impact , and acrylonitrile-butadiene-styrene (ABS) resins, enabling compliance with emerging fire safety standards like California's TB 117 for furniture upholstery introduced in 1975. Initial annual global production volumes were modest, estimated in the thousands of metric tons, but demand surged as regulations mandated retardants in , textiles, and building materials to mitigate risks from flammable synthetics. By the early , PBDEs had achieved broad , with decaBDE comprising over 80% of U.S. production due to its thermal stability in high-temperature applications like circuit boards, while lower-brominated mixtures targeted flexible foams prone to smoldering ignition. and later entered manufacturing in the 1980s, but U.S. firms retained primacy through patented formulations and supply chains integrated with downstream industries. This phase marked PBDEs' transition from laboratory curiosities to ubiquitous additives, driven by empirical testing demonstrating reduced peak heat release rates in treated materials under standardized flammability assays, though long-term environmental fate was not rigorously assessed at commercialization. Commercial production of polybrominated diphenyl ethers (PBDEs) commenced in the , driven by demand for additive retardants in plastics, textiles, and , with volumes expanding significantly through the and as formulations like pentaBDE, octaBDE, and especially decaBDE gained . By 1992, global annual production approached 40,000 tonnes, with decaBDE comprising the majority due to its stability and efficacy in high-temperature applications. Cumulative historical output is estimated at approximately 175 kilotonnes for commercial pentaBDE mixtures, 130 kilotonnes for octaBDE, and 1,600 kilotonnes for decaBDE, reflecting decaBDE's dominance at over 80% of total PBDE production. DecaBDE alone reached an estimated 1.1 million tonnes by 2005, underscoring the scale prior to regulatory interventions. Environmental persistence, bioaccumulation, and emerging toxicity data prompted phase-outs starting in the early 2000s, initially targeting lower-brominated mixtures. In the United States, the three primary manufacturers voluntarily agreed to discontinue production of pentaBDE and octaBDE by December 31, 2004, following negotiations with the Environmental Protection Agency (EPA); the EPA subsequently promulgated Significant New Use Rules (SNURs) in 2006 to require notification for any manufacturing, import, or processing resumption. In the European Union, pentaBDE and octaBDE commercial mixtures were banned for use in new products from August 1, 2004, under Directive 2003/11/EC, aligning with early restrictions under the Stockholm Convention framework, where tetra-, penta-, and hexaBDE congeners (core components of those mixtures) were listed in Annex A in 2009. DecaBDE production persisted longer owing to fewer initial restrictions and its perceived lower , but faced escalating controls; it was added to the Convention's Annex A in 2017, effective from 2019, prohibiting production and use except under specific exemptions. In the , decaBDE manufacturers announced voluntary phase-out by 2013, complemented by EPA actions. Post-phase-out, production shifted to regions with laxer regulations, such as parts of , though global volumes declined sharply in regulated markets; recent EU amendments under the POPs Regulation (effective 2025) further tighten concentration limits in recycled materials to 350 mg/kg by December 30, 2025, and 200 mg/kg by 2027, addressing legacy contamination in waste streams. These measures have correlated with observed reductions in PBDE emissions and environmental levels in monitored regions, though historical stocks continue to release congeners.

Applications and Efficacy

Primary Uses in Products

PBDEs were extensively used as additive flame retardants in polyurethane foams for upholstered furniture, mattresses, and automotive seating to reduce flammability and meet standards such as California's TB 117. The pentaBDE commercial mixture, comprising mainly tetra- and penta-brominated congeners like BDE-47 and BDE-99, was incorporated at levels up to 10-15% by weight in flexible , which constitutes the primary cushioning material in these products. In and electrical applications, PBDEs, particularly the decaBDE formulation (primarily BDE-209), were added to high-impact housings for televisions, computers, and other consumer devices, as well as to wire and cable insulation, to enhance resistance in polymeric materials. OctaBDE mixtures, containing hexa- through octa-brominated congeners, found use in acrylonitrile-butadiene-styrene (ABS) plastics for business machine casings and similar equipment. Additional applications included textiles such as draperies, carpet padding, and fabrics, where PBDEs helped achieve compliance with standards like NFPA 701 for retardancy, though usage volumes were lower compared to foams and plastics. These uses spanned consumer goods produced from the 1970s through the early 2000s, prior to voluntary phase-outs by major manufacturers in response to environmental and concerns.

Fire Safety Benefits and Supporting Evidence

Polybrominated diphenyl ethers (PBDEs), particularly the penta-BDE formulation, have been incorporated into foams used in upholstered furniture and mattresses to enhance resistance to ignition from small open flames or smoldering sources, such as cigarettes, thereby aiming to delay initiation and growth. These additives function primarily in the gas phase during , releasing radicals that scavenge highly reactive and hydroxyl radicals, interrupting the propagation of chain reactions and reducing spread. This mechanism has been demonstrated in bench-scale tests, where PBDE-treated materials exhibit prolonged time-to-ignition and lower peak release rates compared to untreated counterparts under controlled heating conditions. In electronics, such as television enclosures made from high-impact polystyrene, decabromodiphenyl ether (deca-BDE) contributes to fire containment by slowing combustion propagation, with estimates indicating that brominated flame retardants in these applications prevent approximately 190 fatalities annually in the United States by averting rapid fire spread in electrical faults or external ignitions. Full-scale incident data, including the 2005 Air Canada Flight 581 crash fire in Toronto, attribute survivor escapes to the flame-retardant properties of interior materials containing brominated compounds, which limited fire intensity and provided critical evacuation time. Broader regulatory impacts, such as the United Kingdom's 1988 furniture fire safety standards mandating flame retardants (including brominated types), correlate with reductions in fire-related deaths and injuries, saving an estimated 230 lives and preventing over 2,000 injuries per year. Supporting test data from the National Institute of Standards and Technology (NIST) indicate that flame-retardant treatments, including those akin to PBDE applications, can extend escape times by up to 15-fold in simulated compartment fires by mitigating early heat release and risks. However, efficacy in upholstered furniture composites is context-dependent; while PBDEs enable compliance with standards like California's Technical Bulletin 117 (TB 117) for smoldering resistance, full-scale flaming fire tests reveal limited reductions in overall fire growth rates or total heat release, as fabric coverings and foam charring often dominate behavior. Peer-reviewed evaluations, including those by fire researcher Vytenis Babrauskas, confirm no statistically significant differences in peak heat release or ignition propensity between TB 117-compliant PBDE-treated foams and untreated foams in open-flame scenarios, underscoring that benefits are most pronounced against smoldering ignitions rather than propagating flaming fires.

Environmental Behavior

Persistence and Transport Mechanisms

Polybrominated diphenyl ethers (PBDEs) demonstrate significant environmental persistence, particularly lower and medium brominated congeners such as BDE-47, BDE-99, and BDE-153, with estimated half-lives in air, water, soil, and sediment ranging from 2.9 to 11.7 years based on human biomonitoring and environmental modeling data. Higher brominated congeners like BDE-209 exhibit shorter half-lives, approximately 2 weeks in water or 30 minutes under photolytic conditions, though they still accumulate in sediments due to low volatility and strong sorption to particles. This persistence arises from their resistance to hydrolysis, photolysis, and biodegradation, leading to accumulation in soils and sediments where they bind tightly to organic carbon, with partitioning coefficients indicating minimal remobilization. Transport mechanisms for PBDEs primarily involve atmospheric pathways, enabled by their semi-volatility and gas-particle partitioning, which facilitate long-range atmospheric (LRAT) of lower congeners to remote regions such as the . Lighter PBDE components predominate in such distant depositions, as evidenced by field measurements and fate models comparing characteristic travel distances, with aerosol-mediated processes enhancing regional and global dispersal via wet and dry deposition. In aquatic systems, PBDEs exhibit higher concentrations in sediments than overlying —often by a factor of three—due to hydrophobic and settling, limiting aqueous transport but promoting benthic accumulation. deposition from atmospheric inputs further contributes to terrestrial persistence, with minimal leaching into owing to strong adsorption. Overall, these dynamics classify lower PBDEs as persistent organic pollutants capable of widespread environmental cycling, though higher congeners are more localized due to reduced volatility.

Bioaccumulation Dynamics

Polybrominated diphenyl ethers (PBDEs) in organisms primarily due to their hydrophobic nature and high octanol- partition coefficients (log Kow), which range from 5.9 to 10 across congeners, promoting partitioning into tissues over aqueous elimination. Lower-brominated congeners, such as BDE-47 and BDE-99, exhibit stronger potential owing to greater and resistance to metabolic debromination, with bioconcentration factors (BCFs) in fish like carpio exceeding 66,000 for BDE-47. This uptake occurs via direct absorption from across gills or and dietary exposure, where assimilation efficiencies can reach 80-90% in aquatic species. Biomagnification, the net increase in PBDE concentrations across trophic levels, is a hallmark of their dynamics in food webs, driven by efficient trophic transfer and minimal excretion. In freshwater systems like Lake Taihu, , trophic magnification factors (TMFs) for dominant congeners ranged from 1.5 to 3.2, indicating pronounced amplification from to . Marine and ecosystems show comparable patterns, with TMFs often exceeding 1 for lower-brominated PBDEs, though higher-brominated variants (e.g., BDE-209) display reduced due to lower assimilation and potential fecal egestion. Log factors (BAFs) correlate parabolically with log Kow, peaking at intermediate values (around 6-7) before declining for highly brominated congeners, reflecting uptake limitations and enhanced . Factors influencing these dynamics include organism content, which positively correlates with PBDE burdens, and environmental variables like , which can modulate metabolic clearance rates. In terrestrial food chains, plant uptake is limited, but occurs via herbivore-to-predator transfer, with soil-earthworm BAFs highlighting congener-specific . Overall, PBDE persistence in biota—half-lives spanning weeks to years in mammals—sustains elevated body burdens, particularly in top predators like seals and humans, where maternal transfer via further propagates accumulation across generations.

Exposure Assessment

Human Exposure Routes and Levels

Humans are exposed to polybrominated diphenyl ethers (PBDEs) primarily through of indoor house and contaminated food, of contaminated indoor air, and dermal contact with or treated products. In the United States, of house represents 80–90% of total PBDE exposure for the general population, with higher contributions in households containing older electronics, furniture, and . This route is particularly significant for young children due to frequent hand-to-mouth behaviors and crawling on floors. Dietary ingestion, mainly from fatty fish, meat, and dairy products bioaccumulated with lower-brominated congeners like BDE-47 and BDE-99, constitutes a key pathway, especially in regions with elevated environmental such as parts of where it predominates over dust exposure. Inhalation arises from volatilization (off-gassing) of PBDEs from indoor sources like and textiles, with dust-bound particles also contributing via resuspended aerosols. Dermal absorption through contact with dust or direct handling of PBDE-containing materials is generally minor but can be relevant in occupational settings involving or manufacturing residues. Serum PBDE concentrations in the U.S. population peaked around the early prior to voluntary phase-outs. In the National Health and Nutrition Examination Survey (NHANES) 2003–2004, median total PBDE levels (sum of 10 congeners including BDE-47, -99, -100, and -153) were measured as follows:
Demographic GroupMedian ΣPBDE (ng/g lipid weight)
Women aged 16–49 years44
Adolescents aged 12–17 years52.9
These levels varied by ethnicity, with Mexican-American adolescents showing higher medians (62.9 ng/g lipid) potentially linked to dietary or housing factors. Post-phase-out of pentaBDE and octaBDE (2004) and decaBDE (2013), serum PBDE concentrations have declined across NHANES cycles, with reductions most pronounced for lower-brominated congeners, though persistence in legacy products sustains ongoing low-level exposure. Breast milk and adipose tissue levels mirror serum trends, with historical U.S. medians around 20–50 ng/g lipid for total PBDEs, serving as a vector for infant exposure via nursing. Serum concentrations of (PBDEs) in the U.S. population, as measured in the National Health and Nutrition Examination Survey (NHANES), rose substantially from the 1970s through the early 2000s, coinciding with peak commercial production and use. Levels of dominant congeners such as BDE-47, BDE-99, and BDE-100 peaked around the 2003–2004 survey period, reflecting cumulative exposure from household products and dust. Post-phase-out of penta- and octa-BDE formulations in 2004–2005, NHANES data from 2005/06 to 2013/14 documented declines in these congeners across age groups, with per two-year survey period reductions of 14–19% for BDE-47 and BDE-99 in adolescents and adults aged 12–39 years, and 5–6% in those aged 40–59 years. BDE-100 followed a comparable pattern, decreasing 4–15% per period depending on age, while BDE-153 increased by 8–12% in older adults (≥40 years), attributable to its longer elimination and prior . Younger age groups exhibited steeper declines, linked to reduced ongoing intake from legacy sources like indoor dust following regulatory actions. In , temporal monitoring in showed PBDE levels (sum of tri- to hexa-congeners) increasing until the early 2000s before declining sharply after the ban, with concentrations in samples from 1996–2014 dropping by factors of 5–10 for key congeners. Similar post-peak reductions of 78–92% were observed in U.S. and European serum and studies through the , confirming regulatory efficacy in lowering body burdens, though variability persists due to differences in half-lives (e.g., 2–15 years for lower-brominated congeners). Recent data from 2011–2015 in older women indicated modest increases (5–12% annually) for some congeners, suggesting potential plateauing or shifts to alternative exposure routes like diet in specific cohorts. Global meta-analyses affirm overall downward trends in human PBDE exposure since the mid-2000s, with North American levels remaining higher than in or due to earlier and broader use, but continuing to fall in line with production halts. Ongoing emphasizes the need for congener-specific tracking, as higher-brominated forms like BDE-209 show slower or inconsistent declines.

Health Effects Evaluation

Toxicological Studies in Animals and Cells

Studies in rodents have shown that polybrominated diphenyl ethers (PBDEs), particularly lower-brominated congeners like BDE-47 and mixtures such as DE-71, induce hepatotoxicity following oral exposure, manifesting as elevated liver enzymes, hepatocellular hypertrophy, and increased liver weights at doses ranging from 1.7 to 60 mg/kg/day over 10–90 days. Thyroid disruption is a consistent finding, with gestational exposure to BDE-47 (0.2 mg/kg/day) in rats reducing serum thyroxine (T4) levels and altering thyroid gland morphology, potentially contributing to downstream neurodevelopmental effects. Developmental neurotoxicity has been reported in multiple species, including impaired learning, memory deficits, and hyperactivity in offspring of exposed dams, as seen in studies with DE-71 at 60 µg/kg/day during gestation and lactation in mice. Reproductive effects include reduced fertility and altered ovarian function in female rats exposed to BDE-99, alongside potential immunological suppression in both rats and mice. Higher-brominated PBDEs like deca-BDE exhibit effects on liver, thyroid, and neurological endpoints at doses above 100 mg/kg/day, though acute toxicity is generally moderate unless at elevated concentrations. In vitro studies reveal cellular mechanisms underlying these toxicities. PBDEs, including BDE-47 and BDE-209, demonstrate in human neural progenitor cells (hNPCs) at concentrations of 1–30 µM, disrupting differentiation and migration via interference with hormone (TH) signaling pathways, such as reduced expression of TH-responsive genes. Endocrine disruption is evident in cell lines, where BDE-47 and BDE-209 induce through DNA damage and increased micronuclei formation at 10–50 µM exposures. Additional endpoints include , , and altered calcium handling in , contributing to neurotoxic and hepatotoxic profiles in and splenocyte cultures. PBDEs also inhibit sulfotransferase (SULT) and (DI) enzymes in cellular assays, exacerbating TH perturbations at nanomolar to micromolar levels. These findings align with animal data but highlight direct cellular actions independent of systemic metabolism.

Human Epidemiological Data and Associations

Epidemiological studies have primarily examined associations between PBDE exposure—measured via serum, plasma, or levels—and various health outcomes in humans, with prenatal and early childhood exposures receiving particular focus due to in fatty tissues. Cohort studies, such as those involving mother-child pairs, have reported inverse associations between prenatal PBDE concentrations and child neurodevelopmental metrics, including IQ scores and attention-related behaviors. For instance, a and of prenatal serum PBDE levels found a decrease in child IQ by approximately 3.7 points per 10-fold increase in BDE-47 exposure. Similarly, another review indicated prenatal PBDE exposure linked to impairments in executive function and attentional performance in children. These findings draw from prospective cohorts like the Children's Environmental Health Center study, though factors such as and co-exposures to other pollutants complicate interpretations. Thyroid hormone disruptions represent another key area of investigation, with multiple cross-sectional and cohort studies showing inverse relationships between PBDE body burdens and circulating thyroxine (T4) or (T3) levels. In U.S. women from the National Health and Nutrition Examination Survey (NHANES), higher serum PBDEs correlated with increased prevalence, particularly in premenopausal individuals. Childhood exposure studies, including one analyzing NHANES data from 2007–2010, reported subclinical hypothyroidism-like effects, with BDE-153 associated with lower free T4. A Canadian cohort of women aged 30–50 similarly linked plasma PBDEs to elevated hypothyroidism odds. Evidence for remains hypothetical, with some researchers proposing PBDEs contribute to rising incidence via hormone disruption, but direct epidemiological links are lacking and require further validation. Reproductive and metabolic associations include potential impacts on birth outcomes and glucose regulation. Meta-analyses of seven studies identified a significant negative between maternal PBDE levels and birth weight. Prospective cohorts have observed links to altered glucose , with dietary PBDE exposure in a French study associating with higher risk. Childhood PBDE exposures showed inverse relations to adiposity measures in some cohorts, contrasting animal data on . Overall, while associations persist across studies, prospective designs are limited, and reverse causation or residual confounding cannot be ruled out; no definitive causal evidence establishes PBDEs as primary drivers of these outcomes.

Mechanistic Insights and Uncertainties

Polybrominated diphenyl ethers (PBDEs) primarily exert toxicity through disruption of thyroid hormone homeostasis, where congeners such as BDE-47 and BDE-99 compete with thyroxine (T4) for binding to (TTR), a key , thereby reducing circulating T4 levels by 12–92% in studies at doses ≥0.06 mg/kg/day. Hydroxylated metabolites (OH-PBDEs) exhibit higher affinity for TTR (1.2–2-fold greater than T4) and can act as agonists or antagonists at thyroid hormone receptors, modulating such as a 35–45% reduction in T3-dependent transcription observed with BDE-100 . Additionally, PBDEs induce hepatic enzymes like UDP-glucuronosyltransferases (UDPGT) and deiodinases, accelerating T4 clearance and metabolism, with rat pup exposures to DE-71 (a pentaBDE mixture) decreasing serum T4 by 10–60%. In , PBDEs contribute via indirect thyroid-mediated pathways impairing neuronal migration, differentiation, and synaptogenesis, alongside direct cellular effects including through (ROS) generation and in neuroblastoma cells exposed to BDE-47, leading to DNA damage and . is disrupted by congeners like BDE-47 sensitizing ryanodine receptors, elevating intracellular Ca²⁺ and triggering mitochondrial dysfunction and Bax-caspase pathways in PC12 cells. Animal models demonstrate congener-specific outcomes, such as BDE-99 downregulating receptor alpha (TRα) and altering receptor density by 7–31% in mice, correlating with hyperactivity and impaired learning at developmental doses of 0.4–0.8 mg/kg. Uncertainties persist in mechanistic understanding due to species-specific differences, with exhibiting greater thyroid sensitivity from absent (TBG) and faster T4 elimination compared to s, complicating from showing consistent T4 reductions to inconsistent associations (e.g., variable TSH changes at serum levels of 15–20 ng/g ). studies often employ micromolar concentrations exceeding environmental nanomolar exposures, questioning relevance of observed effects like ROS induction, while the higher potency of OH-PBDEs—formed via metabolism—remains understudied in s, with limited on their contributions to neurodevelopmental outcomes. Epidemiological inconsistencies, potential by co-exposures, and gaps in chronic low-dose mixture effects further hinder causal attribution, as studies report subtle neurobehavioral links (e.g., IQ deficits) without clear mechanistic validation.

Ecological Consequences

Impacts on Aquatic and Terrestrial Species

Polybrominated diphenyl ethers (PBDEs) induce in aquatic species, elevating (ROS) levels and disrupting antioxidant defenses such as (SOD) and (CAT) activities. In exposed to BDE-47, this leads to reduced cell viability, increased via upregulated caspase-3 and pathways, and neurodevelopmental impairments including altered retinal structure and hyperactive locomotor responses. Fathead minnows demonstrate reduced (TT4 and TT3) following BDE-209 exposure, alongside diminished pathogen resistance, lower survival rates, and impaired immune organ function. Marine medaka and exhibit similar ROS-mediated liver cell damage and pathway activations (e.g., PI3K and MAPK) from BDE-47. Amphibians face reproductive and developmental toxicity from PBDEs; in Xenopus laevis, BDE-47 exposure disrupts gonadal differentiation. Aquatic invertebrates, including Daphnia magna and rotifers, show neurotoxicity-induced reductions in feeding and reproduction, compounded by ROS generation and shortened lifespan in models like C. elegans. These effects stem from PBDE bioaccumulation, with chronic dietary exposures at environmentally relevant concentrations (7–277 ng/g wet weight food) altering larval development in amphibians. In terrestrial systems, PBDEs bioaccumulate efficiently in soil invertebrates, yielding biota-soil accumulation factors (BSAFs) greater than 1, particularly in earthworms, which transfer congeners like BDE-47 and BDE-99 to predators via dietary pathways. factors (BMFs) exceeding 1 occur in birds such as European starlings at contaminated sites, elevating tissue burdens. Terrestrial-feeding birds accumulate deca-BDE (BDE-209) at higher rates than aquatic counterparts, correlating with disruptions, liver and kidney morphological changes, and multigenerational reproductive declines, as observed in American kestrels exposed to DE-71 mixtures. Terrestrial mammals, including top predators like red foxes, exhibit elevated PBDE concentrations in muscle, liver, and adipose tissues, reflecting trophic transfer and persistence. In birds and mammals, PBDEs suppress immune responses, as evidenced by necrotic lymphocytes and reduced thymic lymphoid cells in broiler chicks dosed with BDE-209, alongside broader endocrine disruptions affecting growth and metabolism. Convergent toxicological outcomes across taxa include neurodevelopmental deficits and , driven by mechanisms such as ROS-induced oxidative damage and signaling interference.

Environmental Contamination Patterns

Polybrominated diphenyl ethers (PBDEs) exhibit widespread environmental contamination due to their persistence, bioaccumulation potential, and historical use in consumer products, leading to detection across global air, water, soil, sediment, and biota matrices. Lower-brominated congeners, such as BDE-47 and BDE-99, dominate atmospheric, water, and biotic concentrations, reflecting preferential volatilization, long-range atmospheric transport, and degradation of higher congeners. Contamination patterns are influenced by proximity to emission sources, including urban areas, electronic waste recycling sites, and landfills, where levels exceed background concentrations by orders of magnitude. In sediments, PBDE distributions vary regionally, controlled by factors such as local inputs, rates, and hydrodynamic conditions, with total concentrations ranging from 1.3 to 18,700 ng/g dry weight globally. Elevated levels, often exceeding 1,000 ng/g, occur near industrial and e-waste hotspots, such as , , where and from dumpsites showed ΣPBDEs up to several μg/g, attributed to leaching from discarded . concentrations typically range from 0.16 to 11.0 ng/L, with higher values in polluted rivers and coastal zones influenced by and discharge. follows similar source-proximate patterns, with urban and e-waste soils exhibiting PBDE levels surpassing those in indoor dust, due to atmospheric deposition and direct disposal. Geographically, industrialized regions like historically hosted peak PBDE stocks and emissions, driving higher baseline contamination compared to less-developed areas, though global transport via air currents results in detectable levels even in remote and environments. Temporal trends indicate stabilization or declines post-2000s regulatory actions; for instance, in biota, PBDE levels dropped nearly 50% in sport fish and 74–95% in bivalves and bird eggs by 2014, correlating with voluntary phase-outs. In OSPAR maritime areas, and biota concentrations have been stable (54%) or declining (46%) over the past two decades, with levels below ecological thresholds. However, ongoing emissions from legacy stocks and informal sustain hotspots, particularly in developing regions with lax controls.

Regulatory Framework

Domestic Policies in Key Regions

In the , commercial pentaBDE and octaBDE formulations were prohibited in 2004 under Directive 2003/11/EC, which mandated member states to ban their marketing and use in concentrations exceeding 0.1% by weight, driven by concerns over persistence and identified in risk assessments. DecaBDE faced restrictions as a (SVHC) under REACH since 2008, with further amendments to the POPs Regulation adopted on August 7, 2025, tightening unintentional trace contaminant limits for all PBDEs to 50 mg/kg in mixtures and articles, down from 500 mg/kg, to minimize legacy emissions. In the United States, federal policy relied on voluntary phase-outs rather than outright bans; major manufacturers agreed with the EPA in 2009 to cease production of pentaBDE, octaBDE, and certain other congeners by December 31, 2009, following state-level actions such as California's 2003 legislation phasing out pentaBDE and octaBDE by 2008. No comprehensive federal ban exists for decaBDE, though it was designated a persistent, bioaccumulative, and toxic (PBT) chemical under the TSCA New Chemicals Program, leading to use reductions in electronics and textiles; monitoring post-phase-out showed declines in environmental levels, attributed to these agreements. Canada implemented prohibitions on the manufacture, use, sale, import, and export of tetraBDE through decaBDE congeners effective September 2008 under the Canadian Environmental Protection Act, following screening assessments deeming them toxic due to potential. Additional regulations in 2022 under the Prohibition of Certain Toxic Substances aligned with Convention amendments, further restricting PBDE concentrations in recycled materials to support ratification. In , a complete ban on import, export, manufacture, and use of pentaBDE, octaBDE, and decaBDE in consumer goods takes effect July 1, 2025, with exemptions for certain industrial applications under permit, reflecting assessments of their environmental persistence and human exposure risks. lacks dedicated national regulations or management policies for PBDEs as of recent evaluations, despite high production and use in , leading to elevated environmental releases compared to regulated regions.

Global Treaties and Compliance

The Stockholm Convention on Persistent Organic Pollutants, adopted in 2001 and entered into force in 2004, designates certain polybrominated diphenyl ethers (PBDEs) as persistent organic pollutants (POPs) requiring global elimination due to their persistence, , and potential toxicity. In 2009, at the fourth in , commercial pentabromodiphenyl ether (containing tetra-, penta-, and hexaBDE congeners) and commercial octabromodiphenyl ether (containing hexa-, hepta-, and some nonaBDE congeners) were added to Annex A of the convention, mandating the elimination of their production and use, with limited exemptions for specific applications like transport vehicles until 2013. Decabromodiphenyl ether (decaBDE), the dominant commercial formulation historically used in plastics and textiles, was listed in Annex A in 2017 at the eighth , with a phase-out deadline set for 2022–2023 depending on the application, though specific exemptions persist for items like parts and electrical components to allow time for alternatives. Parties to the convention, numbering over 180 as of 2023, are required to develop national plans, including inventories of PBDE stocks in products and waste, and apply best available techniques () and best environmental practices (BEP) for handling legacy contamination. Compliance involves reporting progress through national reports to the convention secretariat, with guidance documents aiding inventories and ; for instance, of PBDE-containing plastics is permitted under strict conditions outlined in decisions SC-4/18 and SC-4/14, but destruction of such waste must achieve non-orthogonality thresholds to prevent releases. Despite these measures, challenges persist, including unintentional releases from legacy stocks in , furniture, and vehicles, which continue to emit PBDEs into the environment years after production bans, as evidenced by declining but detectable concentrations in sediments and biota in regions like the OSPAR maritime area. 00114-7/fulltext) Global effectiveness is mixed, with production bans reducing new inputs—evident in post-2009 emission declines modeled from historical stocks—but bioaccumulation of lower-brominated congeners like BDE-153 delays human exposure reductions, and non-compliance in developing nations arises from inadequate enforcement of import/export controls under the Basel Convention's integration with protocols. Recent amendments, such as tightened concentration limits (e.g., 10 mg/kg for general products under EU-aligned interpretations), reflect ongoing efforts to enhance compliance amid loopholes that reintroduce PBDEs into new articles.

Replacement Strategies

Alternative Flame Retardants

Following the voluntary discontinuation of pentaBDE and octaBDE commercial mixtures by December 2004, and the phase-out of decaBDE production by 2013, manufacturers shifted to alternative flame retardants to comply with regulations in foams, , textiles, and insulation materials. These replacements encompass flame retardants (OPFRs), novel brominated flame retardants (NBFRs), and select chlorinated or phosphorus-based compounds, with widespread adoption in consumer goods to maintain flammability standards such as California's TB 117 for furniture. OPFRs, including tris(1,3-dichloro-2-propyl)phosphate (TDCIPP, formerly TDCPP), tris(2-chloroethyl)phosphate (TCEP), and triphenyl phosphate (TPHP), became prominent substitutes in flexible polyurethane foams used for upholstered furniture, mattresses, and vehicle interiors. TDCIPP and TCEP have been detected in over 90% of U.S. house dust samples post-2006, with median concentrations exceeding 1,000 ng/g in some studies, reflecting their increased market penetration after PBDE withdrawal. These compounds function by releasing phosphoric acid during combustion to inhibit flame spread, though their efficacy varies by polymer matrix. NBFRs, such as the components of Firemaster 550—including 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB) and bis(2-ethylhexyl)tetrabromophthalate (TBPH)—emerged as direct replacements for pentaBDE in polyurethane foams. Other NBFRs include bis(2,4,6-tribromophenoxy)ethane (BTBPE), decabromodiphenyl ethane (DBDPE), and tetrabromobisphenol A (TBBPA), the latter applied as a reactive additive in printed circuit boards and epoxy resins for electronics. Hexabromocyclododecane (HBCD), used in expanded polystyrene for building insulation, served as an additive alternative until its listing as a persistent organic pollutant under the Stockholm Convention in 2013, prompting further substitutions. Detection of these alternatives in environmental matrices, such as house dust from homes, showed median levels of EH-TBB rising from 48 ng/g in 2006 to 100 ng/g in 2011, alongside consistent presence of and TDCIPP at maxima over ng/g. While OPFRs were initially presumed less persistent than PBDEs due to shorter environmental half-lives (hours to days), their high production volumes—estimated at over 500,000 tons annually globally—have led to ubiquitous indoor exposures. Research attributes potential developmental neurotoxicity and reproductive effects to certain OPFRs in animal models, fueling debates on substitution efficacy.

Performance Comparisons and Limitations

Halogenated drop-in replacements for PBDEs, such as decabromodiphenyl ethane (DBDPE) and ethanebis(tetrabromophthalimide) (EBTEBPI), demonstrate flame retardancy efficacy equivalent to decaBDE in applications like electrical and electronic equipment and textiles, achieving comparable reductions in ignitability and heat release rates at similar additive loadings. Non-halogenated alternatives, including organophosphorus flame retardants (OPFRs) like and inorganic compounds such as aluminum trihydrate (ATH), also enable compliance with flammability standards but typically require substantially higher loadings—up to 60% by weight in certain plastics—to attain equivalent performance metrics like limiting oxygen index or peak heat release rate. These elevated loadings in non-halogenated systems often result in limitations such as reduced processability, increased product , and diminished mechanical , including lower tensile strength and flexibility in foams or polymers. Alternatives generally incur higher production costs than PBDEs due to the need for greater quantities or specialized formulations. Moreover, while replacements meet small-scale tests (e.g., California's Technical Bulletin 117), empirical data from fire statistics indicate no significant reduction in residential fire deaths or injuries attributable to such standards between 1980 and 2005, suggesting limited translation to real-world fire scenarios. In specific contexts like foams, OPFRs provide condensed-phase char formation for flame inhibition but may exhibit inferior gas-phase radical scavenging compared to PBDEs, necessitating combinations with synergists and potentially yielding higher smoke production during . limitations persist across alternatives, with flame retardancy performance degrading after aging, UV exposure, or mechanical , thereby shortening in end-use products. No universal replacement matches PBDE versatility across types without such trade-offs.

Controversies and Critical Analysis

Risk-Benefit Debates

The primary benefit attributed to PBDEs is their role as additive flame retardants that inhibit ignition and slow flame propagation in used in furniture, , and building materials, theoretically extending escape times during . Proponents, including industry analyses, claim these properties have contributed to ; for example, PBDEs in television casings were estimated to prevent around 190 U.S. fire deaths per year by containing small before escalation. Similarly, their application in and plastics is said to reduce overall fire incidence by releasing radicals that interrupt at high temperatures. Empirical scrutiny, however, challenges the magnitude of these benefits in real-world scenarios. Peer-reviewed evaluations attribute the more than 50% drop in U.S. fire deaths since 1980 primarily to decreased cigarette smoking—a leading ignition source—and enhanced building codes, sprinklers, and smoke detectors, rather than PBDE-treated furniture, which constitutes a minor fraction of fire starts. Furniture fires ignited by open flames or smoldering sources show no proportional decline in fatalities linked to flame retardants, and PBDEs may worsen outcomes by promoting incomplete combustion, yielding higher levels of toxic smoke, carbon monoxide, and hydrogen bromide—factors implicated in up to 75% of fire deaths via inhalation. Risks stem from PBDEs' physical properties as semi-volatile, lipophilic compounds that leach from products, persist in the environment, and bioaccumulate in fatty tissues, leading to chronic human exposure via dust, diet, and air at levels documented in biomonitoring studies (e.g., median serum concentrations of 20–50 ng/g lipid in U.S. adults pre-phaseout). Toxicological and epidemiological data link such exposures to endocrine disruption, including thyroid hormone interference—observed in associations with elevated hypothyroidism prevalence (odds ratio 3.4 for highest PBDE quartile in women aged 30–50)—and neurodevelopmental impairments, such as reduced IQ and attention deficits in children from maternal exposure. Animal models corroborate these via mechanisms like oxidative stress and altered neuronal migration, though human causality remains probabilistic due to confounding variables like co-exposures. Debates hinge on net societal value: industry sources assert fire prevention gains outweigh health costs, citing averted property damage (estimated at billions annually) and lives saved, but independent reviews question this by noting limited efficacy against common smoldering fires and the availability of non-additive alternatives like barrier fabrics or intumescent coatings that achieve similar ignition resistance without bioaccumulation risks. Regulatory bodies, informed by assessments like the EFSA's 2024 toxicological profile update identifying neurotoxicity as a key concern for congeners BDE-47 and BDE-99, have prioritized phase-outs despite sparse direct evidence of population-level harm, reflecting uncertainty in benefit quantification. Post-ban analyses show declining exposures (e.g., 50–90% reductions in since 2004), yet legacy contamination persists, fueling arguments that proactive substitution—rather than reliance on PBDEs—better balances with empirical health protections.

Precautionary Principle vs. Empirical Evidence

The regulation of polybrominated diphenyl ethers (PBDEs) exemplifies the precautionary principle's emphasis on restricting substances based on potential hazards identified in laboratory and environmental persistence data, even amid gaps in human epidemiological causation. In the European Union, penta- and octa-BDE formulations were banned effective August 2004 under Directive 2003/11/EC, driven by evidence of bioaccumulation, long-range transport, and developmental toxicity in rodent studies, including thyroid hormone disruption and behavioral alterations, despite inconclusive direct human harm at typical exposure levels. Similarly, the Stockholm Convention on Persistent Organic Pollutants listed PBDEs in 2009, prioritizing prevention over definitive proof of widespread population-level risks. In contrast, empirical studies have largely reported statistical associations rather than robust causal mechanisms for PBDE-related health effects. Cohort analyses, such as a U.S. and Nutrition Examination Survey-linked study of over 3,000 adults, found higher serum PBDE concentrations correlated with elevated cancer mortality risk ( 1.64 for highest vs. lowest ), but adjustments for confounders like age, , and socioeconomic factors weakened links to all-cause mortality, highlighting challenges in isolating PBDEs from co-exposures. Reviews of neurodevelopmental outcomes indicate suggestive ties to lower IQ scores (e.g., 3-5 point deficits in children with maternal PBDE levels above 10 ng/g ), yet prospective studies struggle with reverse causation and lack randomized controls, with animal-to- extrapolations often overestimating potency due to differences in . Post-phase-out monitoring shows U.S. blood levels declining 70-90% from 2003-2015 peaks, correlating with reduced environmental burdens but no corresponding sharp drops in or reproductive disorders attributable solely to PBDEs. Fire safety data provide countervailing empirical support for PBDEs' societal benefits, which precautionary measures arguably undervalued. Brominated retardants like PBDEs delay ignition in furniture and electronics casings, contributing to a 50% U.S. residential fire death decline from 1980-2010 (from 5,000 to 2,500 annually), with estimates attributing 300-400 prevented smoldering fires yearly to treated furnishings under California Technical Bulletin 117 standards. Industry analyses assert that without such additives, small ignition sources (e.g., cigarettes) escalate to full-room fires 2-5 times faster, potentially increasing injury rates by 15-20% in non-compliant products, though critics note that post-ban alternatives like inert barriers achieve similar delays without persistence issues. Risk-benefit critiques, often from regulatory economists, contend that PBDE restrictions reflect asymmetric precaution—amplifying low-probability harms (e.g., modeled neurotoxicity risks below 1 in 10,000) while discounting quantifiable fire prevention gains, estimated at $5-10 billion in annual U.S. property and health savings. U.S. voluntary phase-outs from 2004 avoided outright bans under TSCA's "unreasonable risk" threshold, reflecting empirical weighing against benefits, yet global treaties' persistence has spurred legacy emissions, with human exposures persisting via dust and diet despite production halts.00114-7/fulltext) This divergence underscores how precaution prioritizes absence of evidence as evidence of absence for safety, potentially at the expense of data-driven trade-offs where PBDEs' causal role in fire suppression outweighs probabilistic health correlations.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.